Cagent Vascular Funding: $41M Raised, Series D (2026)
Cagent Vascular is a Biotech company. It has raised $41M in total funding. Latest round: Series D. Backed by U.S. Venture Partners, Astoria Health Investors.
Cagent Vascular funding overview
Cagent Vascular is a Biotech company. Cagent Vascular has raised $41M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series D announced in July 2026. The round record for Cagent Vascular runs through 2026; nothing later has been disclosed. Investors on record include U.S. Venture Partners, Astoria Health Investors. 2 distinct backers are named across the disclosed rounds.
Cagent Vascular at a glance
Total raised
$41M
Latest round
Series D
Latest round date
July 2026
Industry
Biotech
Notable investors
U.S. Venture Partners, Astoria Health Investors
Frequently asked about Cagent Vascular funding
How much has Cagent Vascular raised?
Cagent Vascular has raised $41M in total disclosed funding across the rounds on record.
Who has invested in Cagent Vascular?
U.S. Venture Partners, Astoria Health Investors are named among the investors backing Cagent Vascular.
What was the latest Cagent Vascular funding round?
The most recent disclosed round is a Series D, announced in July 2026.
Where is Cagent Vascular based?
No headquarters location is disclosed for Cagent Vascular.
What sector does Cagent Vascular operate in?
Cagent Vascular is tracked under Biotech, with $41M in disclosed funding.
When did Cagent Vascular last raise?
The last disclosed Cagent Vascular round closed in July 2026 at Series D.
Totals shown for Cagent Vascular aggregate every disclosed round on file. To see how that compares, browse the Biotech companies and the investors behind them below.
